Acetaminophen alters estrogenic responses in vitro: inhibition of estrogen-dependent vitellogenin production in trout liver cells.

The purpose of this study was to determine if acetaminophen altered estrogen-dependent vitellogenin production in isolated trout liver cells. Estrogen-induced vitellogenesis was studied in liver cells isolated from male trout and cultured in defined medium; vitellogenin secreted into culture medium was quantitated using immunological procedures. Vitellogenin production was absolutely dependent on the addition of estradiol (10(-6) M) to liver cells from male trout. Acetaminophen produced a dose-dependent inhibition of vitellogenin production; approximately 50% inhibition was achieved with 0.05 mM acetaminophen, while 0.3 mM acetaminophen inhibited secreted vitellogenin to undetectable levels. In contrast, these concentrations of acetaminophen (< or = 1 mM) did not significantly alter the production of secreted albumin, determined immunologically, or cause detectable toxicity. Higher doses of acetaminophen were toxic, but did not induce DNA fragmentation in the trout liver cells. Acetaminophen reduction of estradiol-induced vitellogenin production was accompanied by a dose-dependent decrease in vitellogenin mRNA, indicating acetaminophen inhibited a step prior to, or during, formation of vitellogenin mRNA. Estrogen receptor-binding assays demonstrated that acetaminophen did not reduce binding of [3H]-estradiol to trout liver estrogen receptor. In addition, catabolism of estradiol to water-soluble metabolites was not significantly altered by acetaminophen. These studies indicate that non-toxic concentrations of acetaminophen specifically inhibit estrogen-dependent vitellogenin synthesis and suggest that this commonly used drug may alter estrogen-regulated processes.

[1]  P. Walsh,et al.  5 Vitellogenesis and Oocyte Assembly , 1988 .

[2]  G. Flouriot,et al.  Monolayer and aggregate cultures of rainbow trout hepatocytes: long-term and stable liver-specific expression in aggregates. , 1993, Journal of cell science.

[3]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[4]  K. Korach,et al.  Absence of estrogenic activity in some drugs commonly used during pregnancy. , 1986, Biological research in pregnancy and perinatology.

[5]  J. Sumpter,et al.  Vitellogenin synthesis in cultured hepatocytes; an in vitro test for the estrogenic potency of chemicals , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  S. Ray,et al.  Acetaminophen-induced cytotoxicity in cultured mouse hepatocytes: correlation of nuclear Ca2+ accumulation and early DNA fragmentation with cell death. , 1991, Toxicology and applied pharmacology.

[7]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[8]  C. Hughes,et al.  Effects of acetaminophen and nonsteroidal anti-inflammatory drugs on progesterone production by porcine granulosa cells in vitro. , 1987, Reproductive toxicology.

[9]  S. Mäkelä,et al.  Wood-derived estrogens: studies in vitro with breast cancer cell lines and in vivo in trout. , 1996, Toxicology and applied pharmacology.

[10]  A. Colman,et al.  The fate of Xenopus and locust vitellogenins made in Xenopus oocytes. An export-import processing model. , 1983, European journal of biochemistry.

[11]  H. Bryant,et al.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  R. Brueggemeier,et al.  Estrogen metabolism in rat liver microsomal and isolated hepatocyte preparations--I. Metabolite formation and irreversible binding to cellular macromolecules. , 1984, Biochemical pharmacology.

[13]  D. Ciocca,et al.  Estrogen Receptors and Cell Proliferation in Breast Cancer , 1997, Trends in Endocrinology & Metabolism.

[14]  J. Heindel,et al.  Results and evaluations of 48 continuous breeding reproduction studies conducted in mice. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[15]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[16]  D. Cramer,et al.  Over-the-counter analgesics and risk of ovarian cancer , 1998, The Lancet.

[17]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.

[18]  David E. Hinton,et al.  In vitro modulation of 17-β-estradiol-induced vitellogenin synthesis: Effects of cytochrome P4501A1 inducing compounds on rainbow trout (Oncorhynchus mykiss) liver cells , 1996 .

[19]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[20]  N. Copeland,et al.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. , 1997, Molecular endocrinology.

[21]  M. R. Miller,et al.  Acetaminophen toxicity in cultured trout liver cells. II. Maintenance of cytochrome P450 1A1. , 1993, Experimental and molecular pathology.

[22]  M. R. Miller,et al.  Acetaminophen toxicity in cultured trout liver cells. I. Morphological alterations and effects on cytochrome P450 1A1. , 1993, Experimental and molecular pathology.

[23]  J. Clements,et al.  Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.

[24]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[25]  S. Stifani,et al.  Regulation of oogenesis: the piscine receptor for vitellogenin. , 1990, Biochimica et biophysica acta.

[26]  F. Dautry,et al.  Northern blot normalization with a 28S rRNA oligonucleotide probe. , 1989, Nucleic acids research.

[27]  S. Ray,et al.  Acetaminophen-induced cytotoxicity in cultured mouse hepatocytes: effects of Ca(2+)-endonuclease, DNA repair, and glutathione depletion inhibitors on DNA fragmentation and cell death. , 1992, Toxicology and applied pharmacology.

[28]  D. Williams,et al.  Differential responsiveness of avian vitellogenin I and vitellogenin II during primary and secondary stimulation with estrogen. , 1983, Biochemical and biophysical research communications.

[29]  J C Lamb,et al.  Reproductive toxicity evaluation of acetaminophen in Swiss CD-1 mice using a continuous breeding protocol. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[30]  G. Flouriot,et al.  Influence of xenobiotics on rainbow trout liver estrogen receptor and vitellogenin gene expression. , 1995, Journal of molecular endocrinology.

[31]  L. Folmar,et al.  Vitellogenin induction and reduced serum testosterone concentrations in feral male carp (Cyprinus carpio) captured near a major metropolitan sewage treatment plant. , 1996, Environmental health perspectives.

[32]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[33]  S. Safe,et al.  Identification of a functional imperfect estrogen-responsive element in the 5'-promoter region of the human cathepsin D gene. , 1997, Biochemistry.

[34]  M. R. Miller,et al.  DNA repair synthesis in isolated rainbow trout liver cells. , 1989, Carcinogenesis.

[35]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[36]  K. Lonergan,et al.  Hepatic estrogen receptors and plasma estrogen-binding activity in the Atlantic salmon. , 1985, General and comparative endocrinology.

[37]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[38]  L Müller,et al.  Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. , 1996, Mutation research.

[39]  D. Williams,et al.  Biosynthesis of the vitellogenins. Identification and characterization of nonphosphorylated precursors to avian vitellogenin I and vitellogenin II. , 1982, The Journal of biological chemistry.

[40]  K. W. GILES,et al.  An Improved Diphenylamine Method for the Estimation of Deoxyribonucleic Acid , 1965, Nature.

[41]  J. Lech,et al.  In vivo estrogenic activity of nonylphenol in rainbow trout. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[42]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Weisz,et al.  Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. , 1990, Nucleic acids research.

[44]  S. Safe,et al.  Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. , 1996, Molecular endocrinology.

[45]  E. Martinez,et al.  The estrogen‐responsive element as an inducible enhancer: DNA sequence requirements and conversion to a glucocorticoid‐responsive element. , 1987, The EMBO journal.

[46]  M. R. Miller,et al.  Acetaminophen alters estrogenic responses in vitro: stimulation of DNA synthesis in estrogen-responsive human breast cancer cells. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[48]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.